Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LIPE | Q05469 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4028484 | 0.87 | HPGD (0.60) | HPGDGAAALDH1A1LIPESMN1; SMN2 | |
| SCHEMBL16254883 | 0.87 | HPGD (0.49) | HPGDGAAALDH1A1LIPESMN1; SMN2 | |
| SCHEMBL16254877 | 0.85 | MEN1 (0.48) | HPGDGAAALDH1A1LIPESMN1; SMN2 | |
| SCHEMBL16254963 | 0.85 | HPGD (0.47) | HPGDGAAALDH1A1LIPESMN1; SMN2 | |
| SCHEMBL16254904 | 0.84 | HPGD (0.46) | HPGDGAAALDH1A1LIPESMN1; SMN2 | |
| SCHEMBL16254965 | 0.83 | HPGD (0.45) | HPGDGAAALDH1A1LIPESMN1; SMN2 | |
| SCHEMBL16254908 | 0.83 | EPHX2 (0.45) | HPGDGAAALDH1A1LIPESMN1; SMN2 | |
| SCHEMBL16254913 | 0.83 | HPGD (0.45) | HPGDGAAALDH1A1LIPESMN1; SMN2 | |
| SCHEMBL16254690 | 0.81 | LMNA (0.50) | HPGDGAAALDH1A1LIPEPOLB | |
| SCHEMBL4021879 | 0.81 | HPGD (0.52) | HPGDGAAALDH1A1LIPESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889670-B2 | Heterocyclic compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | HPGD 496/4885GAA 4497/4885ALDH1A1 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.